An observational study in Preeclampsia, sponsored by CHA University. Completed. Open to female participants aged 20 Years to 39 Years. Per ClinicalTrials.gov, last updated 2012-07-25.
Sponsored by CHA University · Observational
For the prediction of late-onset preeclampsia (PE) in low risk women, the investigators established a cut-off value for sFlt-1/PlGF ratio and evaluated the combination models of Elecys, second trimester uterine artery (UtA) doppler, and fetoplacental proteins for Down syndrome screening.
A prospective study was carried on in Cha hospital. Serum samples for Down syndrome screening were assayed to estimate pregnancy-associated plasma protein-A (PAPP-A), alpha-fetoprotein , unconjugated estriol, human chorionic gonadotrophin , and inhibin-A. Women screened for Down syndrome were offered UtA Doppler at 20-24 weeks of gestation and then collected serial serum samples for sFlt-1/PlGF ratio at two time points (24-27 and 34-37 weeks' gestation).
882 studies on the registry are indexed under Pre-Eclampsia; 237 are open to participants now.
This study's enrollment of 262 is above the median of 163 across 380 observational studies indexed under Pre-Eclampsia.
Browse Pre-Eclampsia studies →CHA University is the lead sponsor of 54 studies on the registry; 17 are open to participants now.
Counted across the registry records on this site, refreshed daily.
low risk women who had not a risk factor of preeclampsia.
Exclusion Criteria:
identification of patients at risk for late-onset preeclampsia with sFlt-1/PlGF ratio
Time frame: at delivery
identification of patients at risk for late-onset preeclampsia with combined biochemical markers
Time frame: at delivery
No study locations are listed for this record.
This study is completed, as verified in Jul 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
CHA University